Evenity (romosozumab): what it treats, how it is given, side effects
Last updated September 3, 2026.
Evenity (romosozumab) is the bone-builder with a timer: 12 monthly injections that both build new bone and slow its breakdown, for postmenopausal women with osteoporosis at high fracture risk. After the year, the job passes to an antiresorptive drug, because the anabolic effect wanes and the clock is built into the label.
What does it treat?
Osteoporosis in postmenopausal women at high fracture risk: those with a prior osteoporotic fracture or multiple risk factors, or who failed or cannot tolerate other osteoporosis drugs. It inhibits sclerostin, a protein that normally puts brakes on bone formation, so removing the brakes while also slowing resorption gives it a dual action no other class has.
How do you take it?
You do not inject it yourself: a healthcare provider gives two prefilled syringes (210 mg total) under the skin of the stomach area, thigh, or upper arm, once a month, for exactly 12 doses. Calcium and vitamin D repletion runs alongside it, because building bone needs raw materials and because low calcium is a contraindication until corrected. When the 12 months end, an antiresorptive (usually a bisphosphonate or denosumab) follows, otherwise the new bone is not locked in.
Side effects to know
- Common: joint pain, headache, and injection-site reactions.
- Serious: the boxed warning: in one major trial, more heart attacks, strokes, and cardiovascular deaths occurred on romosozumab than on the comparison drug, so it is not for anyone who had a heart attack or stroke in the past year. Also hypocalcemia (worse in kidney disease and dialysis), the class-standard rare osteonecrosis of the jaw and atypical femur fractures, and hypersensitivity.
Who should not take it?
No one with a heart attack or stroke in the preceding year, per the boxed warning, and cardiovascular risk factors weigh into the choice. Uncorrected low blood calcium must be fixed first. Severe kidney disease or dialysis raises the hypocalcemia risk and needs monitoring. Dental work: finish invasive dental procedures before starting when possible, the same jaw-osteonecrosis caution as other potent bone drugs. It is not for men, not for premenopausal women, and not for growing skeletons.
When is it an emergency?
Call 911 for chest pain, facial droop, slurred speech, or one-sided weakness, and for facial swelling or trouble breathing after a dose. Muscle cramps, spasms, or tingling around the mouth can signal low calcium and need prompt attention. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
Why is it limited to 12 months?
Two reasons: the bone-building effect measurably fades after 12 monthly doses, so longer use buys little, and the label caps it there. The design is intentional: one anabolic year to build bone mass fast, then an antiresorptive drug (bisphosphonate or denosumab) to protect it. The year after matters as much as the year on.
What is the heart warning about?
In the ARCH trial comparing it to alendronate, romosozumab patients had more heart attacks, strokes, and cardiovascular deaths. Whether that is a romosozumab risk or an alendronate benefit is debated, but the label treats it as real: no one with a heart attack or stroke in the prior year should get it, and cardiovascular risk factors count in the decision.
How is it different from Tymlos or Forteo?
All three build bone, differently. Tymlos and Forteo mimic parathyroid hormone and are daily self-injections for up to 2 years. Romosozumab blocks sclerostin, builds AND slows breakdown at once, and is a monthly clinic injection for 1 year. Choice comes down to cardiovascular history, injection preference, and insurance.
Why do I need dental work done first?
The potent bone drugs share a rare risk of osteonecrosis of the jaw, concentrated in patients having tooth extractions or invasive dental procedures while on treatment. Getting dental problems fixed before the first dose, then keeping cleanings current, is the standard prevention, not an overreaction.
Do I still need calcium and vitamin D?
Absolutely, and it is built into the label: hypocalcemia must be corrected before starting, and calcium and vitamin D supplementation continues throughout. The drug is the construction crew; calcium is the lumber. Kidney disease makes the monitoring tighter.
What happens if I just stop after the year?
The gains erode. Studies tracking patients who stopped without follow-on therapy show bone density drifting back, while those who transitioned to an antiresorptive kept or extended theirs. The 12-month mark is a scheduled handoff, not a finish line, and your prescriber books the next drug before the last dose.